cellvie

The company develops Therapeutic Mitochondria Transplantation (TMT) to reinvigorate cellular energy metabolism by augmenting or replacing failing mitochondria. Its initial product pipeline targets ischemia-reperfusion injury, specifically aiming to reduce delayed graft function in kidney transplantation. Additionally, the firm is developing a topical mitochondria-enabled gene therapy to treat Epidermolysis Bullosa by restoring Type VII Collagen expression.